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Abstract
Background Age-related macular degeneration (AMD) is an
ocular disease affecting macula — the central part of the
retina, resulting in the degeneration of photoreceptors and
retinal epithelium and causing severe central vision impair-
ment. The pathophysiology of the disease is not completely
known, but a significant role is attributed to genetic factors.
The contribution of oxidative stress in AMD as a trigger of
the degenerative process is well-established. Iron ions may
act as a source of reactive oxygen species; therefore, main-
taining iron homeostasis is important for redox balance in
the organism. Diversity in iron homeostasis genes may
counterpart in unbalanced redox state, and thus be involved
in AMD pathophysiology.
Methods In this work, we searched for an association be-
tween some single nucleotide polymorphisms in the divalent
metal transporter 1 (DMT1) gene intronic IVS4+44C>A
(rs224589) and 3’-UTR c.2044T>C (rs2285230) and envi-
ronmental factors and AMD. Genotyping was performed
using the PCR-RFLP method. DNA was obtained from
436 AMD patients and 168 controls.
Results We did not find any association between the geno-
types of the two polymorphisms and AMD occurrence.
However, we observed that AMD patients living in a rural
environment and having the CC genotype of the IVS4
+44C>A polymorphism had an increased risk of AMD,
while individuals with the CA genotype or the A allele
had a decreased risk of the disease. Moreover, in male
AMD patients the C allele increased the risk of the disease,
while the AA genotype decreased it.
Conclusions These results suggest that the VS4+44C>A
polymorphism of the DMT1 gene may interact with place
of living and gender to modulate the risk of AMD.
Keywords AMD.Age-related maculardegeneration.
Oxidativestress.Iron homeostasis.Genepolymorphism.
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Introduction
Age-related macular degeneration (AMD) is the primary
cause of irreversible vision loss among the elderly, in devel-
oped countries [1]. AMD is ex definitio an age-related
disease, and age is its strongest risk factor. It is estimated
that about 30% of individuals aged 75 or more are diag-
nosed with AMD [2], and this proportion is predicted to be
constantly increasing due to growing live expectancy [3].
Apart from age, in some populations women are reported to
be at a higher risk of AMD [4]. Caucasian ethnicity, as well
as bright iris color, seems to predispose to AMD [5, 6].
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opment has not been unambiguously established [7, 8].
Tobacco smoking is frequently reported to be an important
AMD risk factor [6, 9, 10]. Cardiovascular diseases and
hypertension [11], obesity [12, 13], and high-fat diet [14]
are proved to enhance the risk of AMD, while the associa-
tion of the disease with cataract and cataract surgery needs
further research [15, 16].
AMD is a progressive disease, developing in its late stage
to one of two clinically distinct forms — dry or wet [17]. The
dry form (geographic atrophy) is characterized by drusen
formation and the presence of retinal depigmentation paths
as signs of the degeneration of photoreceptors together with
retinal epithelium [18]. The less prevalent wet form of AMD
(exudative, neovascular) is associated with a majority of total
blindness incidents. The progress of the wet form of the
disease is faster, with apparent choroidal neovascularization
leading to leakages and bleeding into the retina [18, 19]. A
local inflammatory process appears, and a central disciform
scar is formed. Photoreceptors and retinal pigment epithelium
degenerate, leading to the loss of central vision [19].
The etiology of AMD is complex, and the mechanism of
retinal cell death has not been fully understood. The eye is
constantly exposed to short-wavelength light [20]. That
causes a high rate of reactive oxygen species (ROS) gener-
ation within the eye, and this effect is augmented by high
oxygen pressure in the retina [21], high rate of catabolic
reactions in the inner segments of photoreceptors, and the
presence of photoreactive compounds and polyunsaturated
fatty acids (PUFA) in the retinal tissue [22–24]. Inflamma-
tory processes associated with AMD may be an additional
source of ROS [25].
The level of oxidative imbalance in the cell may exceed its
oxidative defense capacity. Then it can cause oxidative dam-
age to different cellular components including DNA, promot-
ing apoptosis [26, 27]. It is proved that iron ions may generate
free radicals in vivo by Fenton reaction, and that a number of
disorders developes through the iron-dependent oxidative
events [28, 29]. Severe iron overload leads to organ failure,
and may cause neurodegeneration [28, 29].
Genetic factors are considered to play an important role
in AMD, as has been shown in a number of family and twin
studies [30]. Several genetic risk markers have been identi-
fied in this disease [23, 31]. It is thought that strong geno-
type–environment interaction appears in the AMD
incidence [32]. In the present report, we show the interplay
between the IVS4+44C>A polymorphism in the DMT1
gene and environmental factors in the AMD occurrence.
T h eD M T 1g e n e( a l s ok n o w na sS L C 1 1 A 2 ,N R A M P 2 )
encodes transmembrane transporter of iron and other
divalent ions. It plays an important role in iron uptake,
and participates in keeping iron homeostasis in the
organism [33].
Materials and methods
Clinical subject
This study included a group of 436 individuals — 290 with
the wet form of AMD, 148 with the dry form of the disease,
and 168 controls. Medical history was obtained from all
subjects, and no one reported any genetic disease. The
patients underwent ophthalmic examination, including
best-corrected visual acuity, intraocular pressure, slit-lamp
examination, and fundus examination, performed with a slit
lamp equipped with either non-contact or contact fundus
lenses. The criteria for enrolling patients into the study
groups were based primarily on clinical usefulness; the dry
form group corresponded to AREDS categories 2, 3 and 4
(geographic atrophy subtype) and the wet to AREDS cate-
gory 4 (choroidal neovascularisation or neovascular macul-
opathy subtype) [34]. Diagnosis of AMD was confirmed by
optical coherence tomography (OCT) and, in some cases,
by fluorescein angiography (FA) and indocyanin green
angiography (ICG). OCT evaluated retinal thickness, the
presence of RPE atrophy, drusen, or subretinal fluid and
intraretinal edema; angiography assessed the anatomical
status of the retinal vessels, the presence of choroidal
neovascularization, and leakage. The OCT examinations
were performed with Stratus OCT model 3000, software
version 4.0 (Oberkochen, Germany). The FA and ICG
examinations were completed with a Topcon TRC-50I
IX fundus camera equipped with the digital Image Net
image system, version 2.14 (Topcon, Tokyo, Japan). A
structured questionnaire was used to get information from
study subjects about lifestyle habits and family/personal
history of AMD. The genetic analyses did not interfere
with diagnostic or therapeutic procedures for the subjects.
The Bioethics Committee of the Medical University of
Warsaw, Poland approved the study, and each patient gave
written informed consent.
DNA isolation
The sample of whole venous blood was collected from
every subject to EDTA-containing tubes. DNA was isolated
from each sample using AxyPrep Blood Genomic DNA
Miniprep kit (Axygen Biosciences, San Francisco, CA,
USA) and stored deep frozen (−20°C) until use.
Genotyping
PCR reaction
Each reaction tube contained 10 ng of genomic DNA, 0.75U
Taq Polymerase (Biotools, Madrid, Spain), 1 × reaction
buffer, 0.5 mM dNTP, 1.5 mM MgCl2 and 0.25 μM of each
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of primers for the IVS4+44C>A polymorphism was as in
reference [35]. The sequences of primers, and length of PCR
and restriction products for both polymorphisms, are given
in Table 1. PCR was run on a Bio-Rad C1000
TM thermo-
cycler (BIO-RAD Laboratories, Hercules, CA, USA) Ther-
mal cycling conditions for the IVS4+44C>A polymorphism
were: initial denaturation step at at 95°C for 3 min, 34 cycles
of denaturation at 95°C for 30 s, annealing at 60°C for 30 s
and amplification at 72°C for 1 min; final extension at 72°C
for 5 min. For the c.2044T>C polymorphism, these condi-
tions were: initial denaturation step at 95°C for 5 min, 33
cycles of denaturation at 95°C for 30 s, annealing at 62°C
for 30 s and amplification at 72°C for 1 min; final extension
at 72°C for 5 min.
Enzyme reactions
Amplified DNA fragment containing IVS4+44C/A site was
incubated with 1.5 U of MnlI restriction enzyme (AKOR
Laboratories,Gdansk,Poland)for4hat37°C,whilefragment
containing the c.2044T>C site was incubated with 1.5U of
RsaI restrictase (Fermentas, Hanover, MD,USA) for 2.5 h in
37°C. The length of digestion products is shown in Table 1.
After digestion samples were separated on 10% poly-
acrylamide gel, electrophoresis was run at 5 V/cm in BLUE-
STAR apparatus (DNA-Gdansk, Gdynia, Poland) in Tris-
borate–EDTA buffer. ΦX-174 DNA/BsuRI (HaeIII) DNA
ladder was utilized as a mass marker. After separation, gels
were stained with ethidium bromide (0.5 μg/ml) and docu-
mented by the digital imaging system InGenius Bio Imaging
(Syngene, Cambridge, UK). Representative gels for geno-
typing the IVS4+44C/A and c.2044T>C polymorphism are
shown in Figs. 1 and 2 respectively.
Data analysis
The allelic frequencies were calculated by gene counting, and
genotypes were scored. The significance of the differences
betweendistributions of genotypesand alleles was tested using
the χ
2 analysis. Unconditional logistic regression analysis was
performed to assess the association between the genotypes of
the polymorphisms and AMD incidence. The genotype-
associated risk was expressed by crude odds ratio with 95%
Table 1 Sequences of primers and lengths of PCR and restriction
products
Genotype/allele Primer sequences and DNA fragments after
digestion [bp]
IVS4+44 F: 5′ GACACATGCAATATCTGACATTG 3′
[352 bp]
a R: 5′ AGGCTACTATCCAACATGCAG 3′
CC 183, 100, 35, 34
CA 217, 183, 100, 35, 34
AA 217, 100, 35
Genotype/allele Primer sequences and DNA fragments after
digestion [bp]
c.2044T>C F: 5′ AAATTTCTCAGCCTTTAAAAATCC3′
[231 bp]
a R: 5′ TTGAAAAGCTGACATTTGCTG 3′
TT 231
TC 231, 145, 86
CC 145, 86
F — forward primer, R — reverse primer,
a) PCR product length
Fig. 1 The frequent gel from the IVS4+44C>A polymorphism analy-
sis. The first line (M) is a DNA ladder. Two non-specific bands were
visible on all gels from IVS4+44C>A site analysis
Fig. 2 The frequent gel from the c.2044T>C polymorphism analysis.
The first line (M) is a DNA ladder
Table 2 Association of AMD with age, sex, tobacco smoking, AMD
in family, BMI, and living environment
Risk Factor OR (95% CI)
1
Age (for +1 year) 1.04 (1.02–1.06); p<0.001
2
Sex (for females) 0.68 (0.4–1.02)
Tobacco smoking (never vs ever) 0.82 (0.55–1.23)
AMD among 1st-degree relatives 10.81 (3.31–35.36); p<0.001
2
Body Mass Index (for +1 BMI unit) 0.97 (0.92–1.02)
Environment (for countryside) 0.74 (0.43–1.28)
1Odds ratio with 95% confidence interval,
2 Chi-square test
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adjusted for possible interfering factors. To verify a potential
gene–environment interaction, the patients and controls were
stratified depending on age, sex, living environment (rural or
urban), smoking status and body mass index (BMI). Multiple
unconditioned logistic regression analyses were run to test the
association of genotypes and environmental and social factors
with AMD occurrence. Statistical analysis was performed
using the Statistica 9.0 package (Statsoft, Tulsa, OK, USA).
Results
The frequencies of genotypes in the groups did not differ
significantly from Hardy-Weinberg equilibrium — p>0.05
for each group. The patient characteristics contained infor-
mation about environmental and social factors having pos-
sible impact on AMD incidence. The analysis of the
association between potential risk factors — age, sex, in-
habitation, smoking habit, and Body Mass Index and AMD
independently from genotypes was performed (Table 2). We
found no association of sex, environment, BMI, and tobacco
smoking with AMD. We observed a significant association
of AMD with age (OR 1.04; 95% CI 1.02–1.06; p<0.001;
for every additional year) and the occurrence of the disease
among 1st-degree relatives (OR 10.81; 95% CI 3.31–35.36;
p<0.001). The next step was to test the association between
the genotypes of both polymorphisms and AMD. No asso-
ciation was found between the risk of AMD and the geno-
types of that polymorphism in the group of all AMD
Table 3 Distribution of genotypes, frequency of alleles of the IVS4+44C>A and c.2044T>C polymorphism of the DMT1 gene, and odds ratios
(OR) with 95% confidence intervals (95% CI) in age-related macular degeneration and controls
Genotype/allele Control (158) AMD (381)
A OR (95% CI)
B OR
adjusted (95% CI)
IVS4+44C>A N (%) N (%)
CC 109 (0.69) 262 (0.69) 0.99 (0.66–1.48) 1.43 (0.79–2.60)
CA 46 (0.29) 109 (0.29) 0.98 (65–1.47) 0.76 (0.41–1.38)
AA 3 (0.02) 10 (0.03) 1.39 (0.38–51.3) 0.38 (0.06–2.51)
C 264 (0.84) 633 (0.83) 0.97 (0.68–1.38) 2.63 (0.40–17.43)
A 52 (0.16) 129 (0.17) 1.03 (0.73–1.47) 0.73 (0.41–1.32)
Genotype/allele Control (168) AMD (436)
A OR (95% CI)
B OR
adjusted (95% CI)
c.2044T>C N (%) N (%)
TT 127 (0.76) 320 (0.73) 0.86 (0.59–1.34) 1.23 (0.65–2.35)
TC 39 (0.23) 108 (0.25) 1.09 (0.72–1.66) 0.79 (0.41–1.53)
CC 2 (0.01) 8 (0.02) 1.55 (0.33–7.38) 1.75 (0.19–15.86)
T 293 (0.87) 748 (0.86) 0.86 (0.59–1.26) 0.87 (0.09–8.37)
C 41 (0.12) 122 (0.14) 1.17 (0.80–1.70) 0.77 (0.40–1.47)
ACrude odds ratio with 95% confidence interval;
B Odds ratio adjusted for age, sex, and environment of living
Table 4 Distribution of geno-
types, frequency of alleles of the
IVS4+44C>A and c.2044T>C
polymorphism of the DMT1
gene, and odds ratios (OR) with
95% confidence intervals (95%
CI) in wet form of age-related
macular degeneration and
controls
A Crude odds ratio with 95%
confidence interval;
B Odds ratio
adjusted for age, sex and envi-
ronment of living
Genotype/allele Control (158) Wet AMD (233)
A OR (95% CI)
B OR
adjusted (95% CI)
IVS4+44C>A N (%) N (%)
CC 109 (0.69) 163 (0.70) 1.13 (0.72–1.76) 1.57 (0.79–3.12)
CA 46 (0.29) 65 (0.28) 0.94 (0.60–1.47) 0.73 (0.37–1.45)
AA 3 (0.02) 5 (0.02) 0.66 (0.16–2.80) 0.16 (0.01–1.95)
C 264 (0.84) 391 (0.84) 1.03 (0.70–1.51) 6.29 (0.51–77.15)
A 52 (0.16) 75 (0.16) 0.97 (0.66–1.43) 0.69 (0.35–1.36)
Genotype/allele Control (168) Wet AMD (290)
A OR (95% CI)
B OR
adjusted (95% CI)
c.2044T>C N (%) N (%)
TT 127 (0.76) 217 (0.75) 0.96 (0.62–1.49) 1.30 (0.62–2.70)
TC 39 (0.23) 70 (0.24) 1.05 (0.67–1.65) 0.82 (0.39–1.71)
CC 2 (0.01) 3 (0.01) 0.87 (0.14–5.25) 1.23 (0.10–15.21)
T 293 (0.87) 504 (0.87) 0.93 (0.62–1.39) 2.62 (0.15–45.54)
C 41 (0.12) 76 (0.13) 1.08 (0.72–1.62) 0.70 (0.33–1.47)
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polymorphism correlated with the wet (Table 4)o rd r y
(Table 5) forms of AMD. Then, the frequency of the com-
plex genotypes of both polymorphic sites were counted
(Table 6.). We found no association between these complex
genotypes and AMD. Then, the patients were classified
depending on potential risk factors, and tested separately.
We found no associations in the case of the c.2044T>C
polymorphisms. We did not observe any interaction of gen-
otypes with age, sex, BMI, or tobacco smoking in AMD
patients (data not shown). However, we found that the CC
genotype of the IVS4+44C>A polymorphism was positive-
ly correlated with AMD (OR 3.50; 95% CI 1.19–10.31; p<
0.05), and the CA genotype and the A allele was inversely
correlated with AMD (OR 0.29; 95% CI 0.10–0.84; p<
0.05) in the group of rural inhabitants (Table 7). No corre-
lation was found in the group of industrial inhabitants. The
AA allele of the IVS4+44C>A polymorphism was negative-
ly correlated with AMD (OR 0.11; 95% CI 0.01–0.98; p<
0.05), while the C allele had a strong positive linkage with
AMD among males (OR 9.56; 95% CI 1.02–89.99; p<0.05)
(Table 8).
Discussion
Age-related macular degeneration is an important health
problem in developed countries. A constantly growing per-
centage of affected individuals and the estimated tendency
that it will rise over the next years is an argument confirm-
ing the urgency of revealing the nature of AMD. That
includes searching for genetic markers of this disease, since
it is established that AMD have features of inherited disease
[30–32]. Several genetic polymorphisms significantly af-
fecting AMD has been identified. These include polymor-
phisms in the CFH, CFB, C2, ERCC6, HTRA, VEGF and
other genes [36]. In the present study, we analyzed poly-
morphisms in the divalent metal transporter 1 (DMT1) gene
and their association with AMD risk. Iron homeostasis is
crucial for proper functioning of the organism, and while
iron deficiency leads to anemia, its excess may cause severe
symptoms. In a number of cases, iron overload leads to
heart, liver or brain damage [37, 38]. It is particularly visible
in hereditary haemochromatosis — genetic defects in one of
the iron homeostasis genes, associated with iron accumula-
tion in the organism [39]. Moreover, the elevated iron level
Table 5 Distribution of geno-
types, frequency of alleles of the
IVS4+44C>A and c.2044T>C
polymorphism of the DMT1
gene, and odds ratios (OR) with
95% confidence intervals (95%
CI) in dry form of age-related
macular degeneration and
controls
A Crude odds ratio with 95%
confidence interval;
B Odds ratio
adjusted for age, sex and envi-
ronment of living
Genotype/allele Control (158) Dry AMD (148)
A OR (95% CI)
B OR
adjusted (95% CI)
IVS4+44C>A N (%) N (%)
CC 109 (0.69) 99 (0.67) 0.91 (0.56–1.47) 1.27 (0.62–2.60)
CA 46 (0.29) 44 (0.30) 1.03 (0.63–1.68) 0.82 (0.40–1.69)
AA 3 (0.02) 5 (0.03) 1.81 (0.42–7.70) 0.65 (0.08–5.19)
C 264 (0.84) 242 (0.82) 0.88 (0.58–1.34) 1.54 (0.19–12.28)
A 52 (0.16) 54 (0.18) 1.13 (0.75–1.72) 0.79 (0.38–1.61)
Genotype/allele Control (168) Dry AMD (146)
A OR (95% CI)
B OR
adjusted (95% CI)
c.2044T>C N (%) N (%)
TT 127 (0.76) 103 (0.71) 0.77 (0.47 - 1.28) 1.14 (0.53–2.48)
TC 39 (0.23) 38 (0.26) 1.16 (0.70 - 1.95) 0.78 (0.35–1.73)
CC 2 (0.01) 5 (0.03) 2.94 (0.56 - 15.40) 2.31 (0.22–24 .03)
T 293 (0.87) 244 (0.84) 0.71 (0.45 - 1.12) 0.43 (0.04–4.52)
C 41 (0.12) 48 (0.16) 1.41 (0.90 - 2.21) 0.88 (0.40–1.90)
Table 6 Distribution of com-
bined genotypes of the IVS4
+44C>A and c.2044T>C poly-
morphism of the DMT1 gene
and odds ratios (OR) with 95%
confidence intervals (95% CI) in
age-related macular degenera-
tion and controls
A Crude odds ratio with 95%
confidence interval;
B Odds ratio
adjusted for age. sex and envi-
ronment of living
Genotype Control (158) AMD (377)
A OR (95% CI)
B OR
adjusted (95% CI)
IVS4+44C>A /c.2044T>C N (%) N (%)
CC/TT 107 (0.68) 249 (0.66) 0.93 (0.62–1.38) 1.33 (0.74–2.38)
CC/TC 2 (0.01) 8 (0.02) 1.69 (0.36–8.05) 2.19 (0.19–25.36)
CC/CC 0 (0) 1 (0) ––
CA/TT 12 (0.08) 25 (0.07) 0.86 (0.42–1.77) 0.73 (0.28–1.96)
CA/TC 34 (0.22) 84 (0.22) 1.05 (0.67–1.64) 0.81 (0.41–1.59)
CA/CC 0 (0) 0 (0) ––
AA/TT 0 (0) 0 (0) ––
AA/TC 1 (0.01) 4 (0.01) 1.68 (0.19–15.18) –
AA/CC 2 (0.01) 6 (0.02) 1.26 (0.25–6.32) 0.91 (0.09–9.32)
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diseases may be connected with an elevated iron level
associated with aging [41, 42]. The mechanism of iron-
related harmful effects in the organism involves the action
of free radicals. Free divalent iron ions participate in the
Fenton reaction, producing highly reactive hydroxyl radi-
cals, which may damage cellular components, including
DNA, and impair DNA repair [43]. An elevated level of
chelatable iron ions has been observed in maculas derived
post mortem from AMD patients [44]. Mice lacking key
genes of iron homeostasis – ceruloplasmin, hephaestin and
hepcidin — developed retinal degeneration with features of
AMD [45, 46]. Similarly, the case of a patient with a defect
in the ceruloplasmin gene has been reported. The patient
suffered from AMD, and an increased iron content in the
macula of the patient was shown [47]. It was also shown, in
a mouse model of AMD and RPE cell line, that iron chela-
tion protected from AMD development [45, 48].
Table 7 Distribution of genotypes. frequency of alleles of the IVS4+44C>A and c.2044T>C polymorphism of the DMT1 gene, and odds ratios
(OR) with 95% confidence intervals (95% CI) in age-related macular degeneration and controls among urban and countryside ancestors
Urban district Countryside
Genotype/allele Control (55) Dry AMD (113)
A OR (95% CI) Control (33) Dry AMD (50)
A OR (95% CI)
IVS4+44C>A N (%) N (%) N (%) N (%)
CC 40 (0.73) 77 (0.68) 0.94 (0.45–1.99) 20 (0.61) 40 (0.80) 3.50 (1.19–10.31) *
CA 13 (0.24) 33 (0.29) 1.24 (0.58–2.68) 13 (0.39) 10 (0.20) 0.29 (0.10–0.84) *
AA 2 (0.04) 3 (0.03) 0.31 (0.04–2.18) 0 (0) 0 (0) –
C 93 (0.85) 187 (0.83) 3.25 (0.46–23.04) 53 (0.80) 90 (0.90) –
A 17 (0.15) 39 (0.17) 1.14 (0.54–2.39) 13 (0.20) 10 (0.10) 0.29 (0.10–0.84) *
Genotype/allele Control (56) Dry AMD (113)
A OR (95% CI) Control (33) Dry AMD (50)
A OR (95% CI)
c.2044T>C N (%) N (%) N (%) N (%)
TT 45 (0.80) 82 (0.73) 0.789 (0.35–1.78) 23 (0.70) 42 (0.84) 3.03 (0.94–9.76)
TC 10 (0.18) 27 (0.24) 1.29 (0.56–3.00) 10 (0.30) 7 (0.14) 0.33 (0.10–1.07)
CC 1 (0.02) 4 (0.03) 0.97 (0.10–9.77) 0 (0) 1 (0.02) –
T 100 (0.89) 191 (0.85) 1.03 (0.10–10.30) 56 (0.85) 91 (0.91) –
C 12 (0.11) 35 (0.15) 1.19 (0.52–2.69) 10 (0.15) 9 (0.09) 0.33 (0.10–1.07)
A Odds ratio adjusted for age and sex; * p<0.05
Table 8 Distribution of genotypes. frequency of alleles of the IVS4+44C>A and c.2044T>C polymorphism of the DMT1 gene, and odds ratios
(OR) with 95% confidence intervals (95% CI) in age-related macular degeneration and controls among males and females
Males Females
Genotype/allele Control (39) Dry AMD (127)
A OR (95% CI) Control (119) Dry AMD (254)
A OR (95% CI)
IVS4+44C>A N (%) N (%) N (%) N (%)
CC 27 (0.69) 78 (0.61) 1.49 (0.49–4.57) 82 (0.69) 184 (0.72) 1.44 (0.71–2.93)
CA 10 (0.26) 44 (0.35) 1.09 (0.34–3.47) 36 (0.30) 65 (0.26) 0.66 (0.32–1.35)
AA 2 (0.05) 5 (0.04) 0.11 (0.01–.98) * 1 (0.01) 5 (0.02) –
C 64 (0.82) 200 (0.79) 9.56 (1.02–9.99) * 200 (0.85) 433 (0.85) –
A 14 (0.18) 54 (0.21) 0.67 (0.22–2.05) 38 (0.16) 75 (0.15) 0.75 (0.37–1.51)
Genotype/allele Control (43) Dry AMD (129)
A OR (95% CI) Control (125) Dry AMD (306)
A OR (95% CI)
c.2044T>C N (%) N (%) N (%) N (%)
TT 32 (0.74) 87 (0.67) 2.00 (0.60–6.66) 95 (0.76) 232 (0.76) 1.04 (0.48–2.27)
TC 10 (0.23) 37 (0.29) 0.57 (0.17–1.94) 29 (0.23) 71 (0.23) 0.91 (0.42–1.99)
CC 1 (0.03) 5 90.04) 0.45 (0.04–5.13) 1 (0.01) 3 (0.01) –
T 74 (0.86) 211 (0.82) 2.24 (0.20–25.72) 219 (0.88) 535 (0.87) –
C 12 (0.14) 47 (0.18) 0.47 (0.14–1.58) 31 (0.12) 77 (0.13) 0.92 (0.42–2.02)
A Odds ratio adjusted for age and living environment; * p<0.05
1062 Graefes Arch Clin Exp Ophthalmol (2012) 250:1057–1065In this paper, we have analyzed two SNP polymorphisms
in the DMT1 gene. This gene has two alternative promoters
and two alternative polyadenylation sites. Four main iso-
forms of DMT1 have been identified. Depending on the
choice of polyadenylation site, the transcript may include
the iron response element (IRE) in the 3’UTR region [49,
50]. The differences between isoforms determine mainly the
tissue-specific expression pattern of the final protein [51].
DMT1 plays a role in iron absorption from the intestine and
its endosomal transport in the cell, being responsible for
cellular distribution of this metal [52, 53]. DMT1 also plays
an important role in cation balance in the nervous system
[52, 53]. There are reports concerning imbalance of iron in
the organism as a consequence of mutations in the DMT1
gene [54, 55]. It has also been postulated that DMT1 plays a
role in the process of neurodegeneration [56]. The IVS4
+44C>A polymorphism is located in the intron 4 of the
DMT1 gene. A nucleotide change inside the intron may
affect significantly either constitutive splicing or alternative
splicing by the corruption of splicing regulatory cis-ele-
ments, giving incorrect isoforms of the protein [57, 58].
This polymorphism has been reported not to be associated
with inflammatory bowel disease [59] and hereditary hae-
mochromatosis [60], but its association with Parkinson’s
disease has been shown [35]. We did not find any report
on the functional significance of the other polymorphism,
c.2044T>C.
Our genotype-independent analysis of potential AMD
risk factors showed an association with age and a strong
association with familial AMD. Therefore, positive AMD
familial history may increase the risk of the occurrence of
the disease among remaining family members. On the other
hand, we found no association of AMD with smoking
status, sex, BMI, and place of living. In particular, the lack
of association of AMD with sex and smoking is somehow
surprising, because several groups have shown a significant
association between tobacco smoking and AMD [61]. Fur-
thermore, female sex was reported as an AMD risk factor in
several populations [4]. We do not have information on the
general association between AMD occurrence and gender in
Poland, so we can conclude that the dependence of the
AMD risk on sex may be population-specific, or that our
studies lacked power to detect this dependence, and further
investigations in the Polish population are needed to clarify
this point. Tobacco smoking is well-confirmed as a modu-
lator of AMD risk, although some groups have reported no
association between smoking and AMD, or only a limited,
borderline association [62–65]. Again, the dependence be-
tween smoking and AMD may be population-specific and
influenced by passive smoking, which should not be ignored
[66]. Stratification of patients depending on age, sex, BMI,
living environment and tobacco smoking status revealed no
correlation between these factors, AMD, and the genotypes
of the c.2044T>C polymorphism. However, in the group of
rural inhabitants, the polymorphism IVS4+44C>A was sig-
nificantly correlated with AMD risk. The C variant seemed
to increase the AMD risk if it occurred among rural inhab-
itants, while the A variant had a protective role. Similarly,
the C variant strongly positively increased AMD risk among
males, and the Avariant decreased the risk in this group. This
is particularly interesting, since in a number of researches in
otherpopulations,femaleswereathigherriskofAMD[4].No
significant influence of a tobacco smoking habit is also worth
emphasizing,astobacco smoking is thought tobea major risk
factor in AMD. Our result showed that the IVS4+44C>A
polymorphism in DMT1 gene may be considered as a poten-
tial environment-dependent risk marker for AMD.
Acknowledgements This work was supported by grant N N402 248
336 from Polish Ministry of Science and Higher Education.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Prevent Blindness America (2002) Vision problems in the U.S.:
prevalence of adult vision impairment and age-related eye disease
in America. Prevent Blindness America, Schaumburg IL, pp 1–21
2. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P,
Vingerling JR, Klein BE, Smith W, De Jong PT (2004) Risk
factors for incident age-related macular degeneration: pooled find-
ings from 3 continents. Ophthalmology 11:1280–1287
3. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon
RE (2007) Fifteen-year cumulative incidence of age-related mac-
ular degeneration: the Beaver Dam Eye Study. Ophthalmology
114:253–262
4. Busch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen
NV (2005) Risk factors for age-related maculopathy in 14-year
follow-up study: the Copenhagen City Eye Study. Acta Ophthal-
mol Scand 83:409–418
5. Frank RN, Puklin JE, Stock C, Canter LA (2000) Race, iris color,
and age-related macular degeneration. Trans Am Ophthalmol Soc
98:109–117
6. Liutkeviciene R, Lesauskaite V, Asmoniene V, Zaliuniene D,
Jasinskas V (2010) Factors determining age-related macular de-
generation: a current view. Medicina 46:89–94
7. West SK, Rosenthal FS, Bressler NM, Bressler SB, MunozB FSL
(1989) Exposure to sunlight and other risk factors for age-related
macular degeneration. Arch Ophthalmol 107:875–879
8. Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD
(2004) Sunlight and the 10-year incidence of age-related maculop-
athy: the Beaver Dam Eye Study. Arch Ophthalmol 122:750–757
9. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly
SP (2005) Smoking and age-related macular degeneration: review
of association. Eye 19:935–944
10. Chakravarthy U, Augood C, Bentham GC, de Jong PT, Rahu M,
Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR,
Viogue J, Young IS, Fletcher AE (2007) Cigarette smoking and
age-related macular degeneration in the EUREYE study. Ophthal-
mology 114:1157–1163
Graefes Arch Clin Exp Ophthalmol (2012) 250:1057–1065 106311. Hogg RE, Woodside JV, Gilchrist SE, Graydon R, Fletcher AE,
Chan W, Knox A, Cartmill B, Chakravarthy U (2008) Cardiovas-
cular disease and hypertension are strong risk factors for choroidal
neovascularization. Ophthalmology 115:1046–1052
12. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL (2005)
Risk factors for the incidence of advanced age-related macular
degeneration in the Age-Related Eye Disease Study (AREDS):
AREDS report No. 19. Ophthalmology 112:533–539
13. Peeters A, Magliano DJ, Stevens J, Duncan BB, Klein R, Wong
TY (2008) Changes in abdominal obesity and age-related macular
degeneration. Arch Ophthalmol 126:1554–1560
14. SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL 3rd,
Gensler GR, Kurinij N, Lindblad AS, Milton RC, Seddon JM,
Sperduto RD, Age-Related Eye Disease Study Research Group
(2007) The relationship of dietary lipid intake and age-related
macular degeneration in a case-control study: AREDS Report
No. 20. Arch Ophthalmol 125:671–679
15. Ho L, Boekhoorn SS, Liana, van Duijn CM, Uitterlinden AG,
Hofman A, de Jong PT, Stijnen T, Vingerling JR (2008) Cataract
surgery and the risk of aging macula disorder: The Rotterdam
Study. Invest Ophthalmol Vis Sci 49:4795–4800
16. Klein BE, Klein R, Lee KE (1998) Incidence of age-related cata-
ract: the Beaver Dam Eye Study. Arch Ophthalmol 116:219–225
17. Hamdi HK, Kenney C (2003) Age-related macular degeneration: a
new viewpoint. Front Biosci 8:e305–e314
18. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY (2008) Age-
related macular degeneration. Lancet 372:1835–1845
19. Bressler SB (2009) Introduction: Understanding the role of angio-
genesis and antiangiogenic agents in age-related macular degener-
ation. Ophthalmology 116(10 suppl):S1–S7
20. Sliney DH (2002) How light reaches the eye and its components.
Int J Toxicol 21:501–509
21. Roth F, Bindewald A, Holz FG (2004) Key pathologic pathways in
age-related macular disease. Graefes Arch Clin Exp Ophthalmol
242:710–716
22. Chalam KV, Khetpal V, Rusovici R, Balaiya S (2011) A review:
role of ultraviolet radiation in age-related macular degeneration.
Eye Contact Lens 37:225–232
23. Ding X, Patel M, Chan CC (2009) Molecular pathology of age-
related macular degeneration. Prog Retin Eye Res 28:1–18
24. Murdaugh LS, Avalle LB, Mandal S, Dill AE, Dillon J, Simon JD,
Gaillard ER (2010) Compositional studies of human RPE lipofus-
cin. J Mass Spectrom 45:1139–1147
25. Lau L, Chiou SH, Liu CJ, Yen MY, Wei YH (2011) The effect of
photo-oxidative stress and inflammatory cytokine on complement
factor H expression in retinal pigment epithelial cells. Invest Oph-
thalmol Vis Sci 52:6832–6841
26. Kasahara E, Lin LR, Ho YS, Reddy VN (2005) SOD2 protects
against oxidation-induced apoptosis in mouse retinal pigment ep-
ithelium: implications for age-related macular degeneration. Invest
Ophthalmol Vis Sci 46:3426–3434
27. Justilien V, Pang JJ, Renganathan K, Zhan X, Crabb JW, Kim SR,
Sparrow JR, Hauswirth WW, Lewin AS (2007) SOD2 knockdown
mousemodelofearlyAMD.InvestOphthalmolVisSci48:4407–4420
28. Pietrangelo A (2010) Hereditary hemochromatosis: pathogenesis,
diagnosis, and treatment. Gastroenterology 139:393–408
29. Brissot P, Bardou-Jacquet E, Troadec MB, Mosser A, Island ML,
Detivaud L, Loreal O, Jouanolle AM (2010) Molecular diagnosis of
genetic iron-overload disorders. Expert Rev Mol Diagn 10:755–763
30. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE,
Spector TD (2002) Genetic influence on early age-related macul-
opathy: a twin study. Ophthalmology 109:730–736
31. Montezuma SR, Sobrin L, Seddon JM (2007) Review of genetics in
age related macular degeneration. Semin Ophthalmol 22:229–240
32. ChenY,BedellM,ZhangK(2010)Age-relatedmaculardegeneration:
genetic and environmental factors of disease. Mol Interv 10:271–281
33. Wang D, Song Y, Li J, Wang C, Li F (2011) Structure and metal
ion binding of the first transmembrane domain of DMT1. Biochim
Biophys Acta 1808:1639–1644
34. Age-Related Eye Disease Study Group (2000) Risk factors asso-
ciated with age-related macular degeneration. A case-control study
in the age-related eye disease study: Age-Related Eye Disease
Study Report Number 3. Ophthalmology 107:2224–2232
35. Kayaalti Z, Odabasi M, Soylemezoglu T (2011) Genotype and
allele frequencies of divalent metal transporter 1 polymorphism
in Turkish population. Mol Biol Rep 38:2679–2684
36. Ross JR, Verma V, Rosenberg IK, Chan CC, Tuo J (2007) Genetic
markers and biomarkers for age-related macular degeneration.
Expert Rev Ophthalmol 2:443–457
37. Weinberg ED (2010) The hazards of iron loading. Metallomics
2:732–740
38. Shander A, Cappellini MD, Goodnough LT (2009) Iron overload
and toxicity: the hidden risk of multiple blood transfusions. Vox
Sang 97:185–197
39. Camaschella C, Poggiali E (2011) Inherited disorders of iron
metabolism. Curr Opin Pediatr 23:14–20
40. Steegmann-Olmedillas JL (2011) The role of iron in tumor cell
proliferation. Clin Transl Oncol 13:71–76
41. Brewer GJ (2010) Risk of copper and iron toxicity during aging in
humans. Chem Res Toxicol 23:319–326
42. Xu J, Marzetti E, Seo AY, Kim JS, Prolla TA, Leeuwenburgh C
(2010) The emerging role of iron dyshomeostasis in the mitochon-
drial decay of aging. Mech Ageing Dev 131:487–493
43. Jomova K, Valko M (2011) Advances in metal-induced oxidative
stress and human disease. Toxicology 283:65–87
44. Hahn P, Milam AH, Dunaief JL (2003) Maculas affected by age-
related macular degeneration contain increased chelatable iron in
the retinal pigment epithelium and Bruch’s membrane. Arch Oph-
thalmol 121:1099–1105
45. Hadziahmetovic M, Song Y, Ponnuru P, Iacovelli J, Hunter A,
Haddad N, Beard J, Connor JR, Vaulont S, Dunaief JL (2011)
Age-dependent retinal iron accumulation and degeneration in hep-
cidin knockout mice. Invest Ophthalmol Vis Sci 52:109–118
46. Hadziahmetovic M, Song Y, Wolkow N, Iacovelli J, Grieco S, Lee
J ,L y u b a r s k yA ,P r a t i c oD ,C o n n e l l yJ ,S p i n oM ,H a r r i sZ L ,
Dunaief JL (2011) The oral iron chelator deferiprone protects iron
overload-induced retinal degeneration. Invest Ophthalmol Vis Sci
52:959–968
47. Dunaief JL, Richa C, Franks EP, Schultze RL, Aleman TS,
Schenck JF, Zimmerman EA, Brooks DG (2005) Macular degen-
eration in a patient with aceruloplasminemia, a disease associated
with retinal iron overload. Ophthalmology 112:1062–1065
48. Lukinova N, Iacovelli J, Dentchev T, Wolkow N, Hunter A,
Amado D, Ying GS, Sparrow JR, Dunaief JL (2009) Iron chelation
protects the retinal pigment epithelial cell line ARPE-19 against
cell death triggered by diverse stimuli. Invest Ophthalmol Vis Sci
50:1440–1447
49. Garrick DM, Garrick ML (2009) Cellular iron transporters. Bio-
chim Biophys Acta 1790:309–325
50. Garrick DM (2011) Human iron transporters. Genes Nutr 6:45–54
51. Mackenzie B, Takanaga H, Hubert N, Rolfs A, Hediger MA
(2007) Functional properties of multiple isoforms of human diva-
lent metal-ion transporter 1 (DMT1). Biochem J 403:59–69
52. Mackenzie B, Garrick MD (2005) Iron Imports. II. Iron uptake at
the apical membrane in the intestine. Am J Physiol Gastrointest
Liver Physiol 289:G981–G986
53. Andrews NC (1999) The iron transporter DMT1. Int J Biochem
Cell Biol 31:991–994
54. Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak K,
Ponka P, Divoky V, Prchal JT (2005) Identification of a human
mutation of DMT1 in a patient with microcytic anemia and iron
overload. Blood 105:1337–1342
1064 Graefes Arch Clin Exp Ophthalmol (2012) 250:1057–106555. Iolascon A, d’Apolito M, Servedio V, Cimmino F, Piga A,
Camaschella C (2006) Microcytic anemia and hepatic iron overload
in a child with compound heterozygous mutations in DMT1
(SLC11A2). Blood 107:349–354
56. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D,
Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick
LM, Nunez MT, Garrick MD, Raisman-Vozari R, Hirch EC (2008)
Divalent metal transporter 1 (DMT1) contributes to neurodegenera-
tion in animal models of Parkinson’sd i s e a s e .P r o cN a t lA c a dS c i
USA 105:18578–18583
57. Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and
disease. Biochim Biophys Acta 1792:14–26
58. Ward AJ, Cooper TA (2010) The pathobiology of splicing. J Pathol
220:152–163
59. Stokkers PC, Huibregtse K Jr, Leegwater AC, Reitsma PH, Tytgat
GN, van Deventer SJ (2000) Analysis of a positional candidate
gene for inflammatory bowel disease: NRAMP2. Inflamm Bowel
Dis 6:92–98
60. Keller T, Ryan E, Barrett S, O’Keane C, Crowe J (2004) DMT1
genetic variability is not responsible for phenotype variability in
hereditary hemochromatosis. Blood Cells Mol Dis 33:35–39
61. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly
SP (2005) Smoking and age-related macular degeneration: a re-
view of association. Eye 19:935–944
62. Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L (1996) Risk
factors of age-related maculopathy in a population 70 years of age
or older. Ophthalmology 103:871–877
63. Chaine G, Hullo A, Sahel J, Soubrane G, Espinasse-Berrod MA,
Schutz D, Bourguignon C, Harpev C, Brault Y, Coste M, Moccatti
D, Bourgeois H (1998) Case-control study of the risk factors for
age related macular degeneration. France-DLMA Study Group. Br
J Ophthalmol 82:996–1002
64. Klein R, Klein BE, Moss SE (1998) Relation of smoking to the
incidence of age-related maculopathy. The Beaver Dam Eye Study.
Am J Epidemiol 147:103–110
65. Klein R, Klein BE, Tomany SC, Moss SE (2002) Ten-year inci-
dence of age-related maculopathy and smoking and drinking: the
Beaver Dam Eye Study. Am J Epidemiol 156:589–598
66. Pons M, Marin-Castano ME (2011) Nicotine increases the VEGF/
PEDF ratio in retinal pigment epithelium: a possible mechanism
for CNVin passive smokers with AMD. Invest Ophthalmol Vis Sci
52:3842–3853
Graefes Arch Clin Exp Ophthalmol (2012) 250:1057–1065 1065